https://orcid.org/0000-0001-9658-1409
References
- Maltseva N, Borzova E, Fomina D, COLD-CE Steering Committee, et al. Cold urticaria – what we know and what we do not know. Allergy. 2021;76(4):1077–1094.
- Młynek A, Magerl M, Siebenhaar F, et al. Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria. Br J Dermatol. 2010;162:198–200.
- Neittaanmäki H. Cold urticaria: clinical findings in 220 patients. J Am Acad Dermatol. 1985;13(4):636–644.
- Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016;71(6):780–802.
- Metz M, Schütz A, Weller K, et al. Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial. J Allergy Clin Immunol. 2017;140(3):864–867.e5.
- Kaplan AP, Garofalo J, Sigler R, et al. Idiopathic cold urticaria: in vitro demonstration of histamine release upon challenge of skin biopsies. N Engl J Med. 1981;305(18):1074–1077.
- Poulsen LK, Hummelshoj L. Triggers of IgE class switching and allergy development. Ann Med. 2007;39(6):440–456.
- Ferrucci S, Benzecry V, Berti E, et al. Rapid disappearance of both severe atopic dermatitis and cold urticaria following dupilumab treatment. Clin Exp Dermatol. 2020;45(3):345–346.
- Lee JK, Simpson RS. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2019;7(5):1659–1661.e1.